Ana Letícia Malheiros Silveira1, Adaliene Versiani Matos Ferreira1,2, Marina Chaves de Oliveira1,2, Milene Alvarenga Rachid1,3, Larissa Fonseca da Cunha Sousa1, Flaviano Dos Santos Martins4, Ana Cristina Gomes-Santos5, Angelica Thomaz Vieira1, Mauro Martins Teixeira6. 1. Immunopharmacology, Department of Biochemistry and Immunology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. 2. Department of Nutrition, Nursing School, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 3. Department of General Pathology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 4. Biotherapeutic Agents, Department of Microbiology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 5. Immunobiology, Department of Biochemistry and Immunology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. 6. Immunopharmacology, Department of Biochemistry and Immunology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. mmtex.ufmg@gmail.com.
Abstract
PURPOSE: Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders with important impact on global health. Prebiotic and probiotic strategies are thought to be useful in the context of experimental IBD. Here, we compared the effects of preventive versus therapeutic treatment with a high fiber diet (prebiotic) in combination or not with Bifidobacterium longum (probiotic) in a murine model of chronic colitis. METHODS: Colitis was induced by adding dextran sulfate sodium (DSS) to drinking water for 6 days (acute colitis) or for 5 cycles of DSS (chronic colitis). RESULTS: Administration of the high fiber diet protected from acute colitis. Protection was optimal when diet was started 20 days prior to DSS. A 5-day pretreatment with acetate, a short-chain fatty acid, provided partial protection against acute colitis. In chronic colitis, pretreatment with the high fiber diet attenuated clinical and inflammatory parameters of disease. However, when the treatment with the high fiber diet started after disease had been established, overall protection was minimal. Similarly, delayed treatment with acetate or B. longum did not provide any protection even when the probiotic was associated with the high fiber diet. CONCLUSION: Preventive use of a high fiber diet or acetate clearly protects mice against acute and chronic damage induced by DSS in mice. However, protection is lost when therapies are initiated after disease has been established. These results suggest that any therapy aimed at modifying the gut environment (e.g., prebiotic or probiotic strategies) should be given early in the course of disease.
PURPOSE:Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders with important impact on global health. Prebiotic and probiotic strategies are thought to be useful in the context of experimental IBD. Here, we compared the effects of preventive versus therapeutic treatment with a high fiber diet (prebiotic) in combination or not with Bifidobacterium longum (probiotic) in a murine model of chronic colitis. METHODS:Colitis was induced by adding dextran sulfate sodium (DSS) to drinking water for 6 days (acute colitis) or for 5 cycles of DSS (chronic colitis). RESULTS: Administration of the high fiber diet protected from acute colitis. Protection was optimal when diet was started 20 days prior to DSS. A 5-day pretreatment with acetate, a short-chain fatty acid, provided partial protection against acute colitis. In chronic colitis, pretreatment with the high fiber diet attenuated clinical and inflammatory parameters of disease. However, when the treatment with the high fiber diet started after disease had been established, overall protection was minimal. Similarly, delayed treatment with acetate or B. longum did not provide any protection even when the probiotic was associated with the high fiber diet. CONCLUSION: Preventive use of a high fiber diet or acetate clearly protects mice against acute and chronic damage induced by DSS in mice. However, protection is lost when therapies are initiated after disease has been established. These results suggest that any therapy aimed at modifying the gut environment (e.g., prebiotic or probiotic strategies) should be given early in the course of disease.
Entities:
Keywords:
Colitis; DSS; High fiber diet; Inflammatory bowel disease
Authors: Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho Journal: Science Date: 2006-10-26 Impact factor: 47.728
Authors: Anastasiya Slyepchenko; Andre F Carvalho; Danielle S Cha; Siegfried Kasper; Roger S McIntyre Journal: CNS Neurol Disord Drug Targets Date: 2014 Impact factor: 4.388
Authors: Kendle M Maslowski; Angelica T Vieira; Aylwin Ng; Jan Kranich; Frederic Sierro; Di Yu; Heidi C Schilter; Michael S Rolph; Fabienne Mackay; David Artis; Ramnik J Xavier; Mauro M Teixeira; Charles R Mackay Journal: Nature Date: 2009-10-29 Impact factor: 49.962
Authors: Nicholas Arpaia; Clarissa Campbell; Xiying Fan; Stanislav Dikiy; Joris van der Veeken; Paul deRoos; Hui Liu; Justin R Cross; Klaus Pfeffer; Paul J Coffer; Alexander Y Rudensky Journal: Nature Date: 2013-11-13 Impact factor: 49.962
Authors: Eduardo Mendes; Beatriz G Acetturi; Andrew M Thomas; Flaviano Dos S Martins; Amanda R Crisma; Gilson Murata; Tárcio T Braga; Niels O S Camâra; Adriana L Dos S Franco; João C Setubal; Willian R Ribeiro; Claudete J Valduga; Rui Curi; Emmanuel Dias-Neto; Wothan Tavares-de-Lima; Caroline M Ferreira Journal: Front Microbiol Date: 2017-09-11 Impact factor: 5.640
Authors: Ian M Cartwright; Valerie F Curtis; Jordi M Lanis; Erica E Alexeev; Nichole Welch; Matthew S Goldberg; Rachel E M Schaefer; Rachel Y Gao; Carlene Chun; Blair Fennimore; Joseph C Onyiah; Mark E Gerich; Peter J Dempsey; Sean P Colgan Journal: Mucosal Immunol Date: 2019-12-02 Impact factor: 7.313